Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

Dimitrios C. ZiogasDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Efstathios KastritisDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Correspondence[email protected]

Evangelos TerposDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Maria RoussouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Magdalini MigkouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Maria GavriatopoulouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Despoina SpanomichouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Evangelos Eleutherakis-PapaiakovouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Despoina FotiouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Ioannis PanagiotidisDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Eftychia KafantariDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Erasmia PsimenouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Ioannis BoletisDepartment of Nephrology and Renal Transplantation Unit, Laiko General Hospital, Athens, Greece;

Demetrios V. VlahakosRenal Unit, Attikon General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Hariklia GakiopoulouDepartment of Histopathology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Charis MatsoukaDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

Meletios A. DimopoulosDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece;

show all

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

ICMJE Form for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date